An interventional study of PROTECT-ED Care Coordination in Opioid Overdose Prevention, HIV Prevention and Care and Harm Reduction, sponsored by Johns Hopkins University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Johns Hopkins University · Not applicable, Interventional, and Health services research
The Prevention and Rapid Outreach for Treatment, Engagement, and Care Transition from the Emergency Department (PROTECT-ED) study evaluates an emergency department-based implementation strategy designed to improve delivery of evidence-based overdose and HIV prevention services during community re-entry.
Background Individuals returning to the community following incarceration experience one of the highest periods of preventable morbidity and mortality observed in clinical medicine. During the weeks and months following release from correctional facilities, rates of fatal opioid overdose increase by as much as 10- to 100-fold, while the risk of HIV acquisition is estimated to be 6- to 20-fold higher than that of the general population. These risks reflect the convergence of opioid use disorder, disrupted healthcare access, unstable housing, poverty, stigma, untreated mental illness, and fragmented transitions between correctional and community healthcare systems. Although effective biomedical interventions exist--including medications for opioid use disorder (MOUD) and HIV pre-exposure prophylaxis (PrEP)--many recently incarcerated individuals do not successfully engage in or remain connected to these services during community re-entry.
Historically, efforts to improve continuity of care have focused on correctional health systems and community re-entry programs. These approaches have demonstrated important benefits but remain limited by incomplete implementation, inconsistent access across jurisdictions, and substantial loss to follow-up during the transition from incarceration to community living. Consequently, many individuals with ongoing opioid-related and HIV-related risks remain disconnected from preventive healthcare during the period of greatest vulnerability.
The emergency department represents an underutilized opportunity to address this implementation gap. Between one-quarter and one-half of individuals released from incarceration seek care in an emergency department within the first year following release, and for many, the emergency department serves as the only point of contact with the healthcare system. Contemporary emergency departments have increasingly expanded beyond episodic acute care to incorporate evidence-based public health interventions, including overdose prevention, medications for opioid use disorder, HIV screening, and initiation of HIV pre-exposure prophylaxis. These developments position the emergency department as a critical venue for delivering integrated preventive services to individuals who may otherwise remain unreached by traditional healthcare systems.
PROTECT-ED was developed to leverage this unique healthcare touchpoint by integrating peer-delivered prevention services, evidence-based biomedical prevention, harm reduction, and facilitated linkage to ongoing community care into a single emergency department encounter. Rather than evaluating the efficacy of MOUD or PrEP--which are already supported by extensive evidence--the study evaluates an implementation strategy designed to improve the reach, uptake, and continuity of these established interventions among recently incarcerated individuals. The intervention is informed by the Behavioral Model for Vulnerable Populations, which recognizes that healthcare utilization is shaped by predisposing characteristics, enabling resources, and perceived and evaluated need for care. By addressing barriers across each of these domains during an existing emergency department visit, PROTECT-ED seeks to improve engagement with preventive services during community re-entry.
Aims The study consists of three integrated aims. Aim 1 focuses on refinement of the PROTECT-ED intervention through participatory prototyping involving individuals with lived experience, clinicians, correctional health partners, community-based organizations, and other stakeholders.
Aim 2 evaluates the feasibility and preliminary clinical outcomes of the refined PROTECT-ED intervention through a prospective implementation trial enrolling 120 adults recently released from incarceration.
Aim 3 evaluates implementation outcomes using mixed methods guided by the Practical, Robust, Implementation and Sustainability Model (PRISM). Quantitative and qualitative findings will characterize intervention reach, acceptability, contextual determinants, and implementation barriers and facilitators.
Conceptual Framework The PROTECT-ED intervention is informed by the Behavioral Model for Vulnerable Populations, which recognizes that healthcare utilization is influenced by predisposing characteristics, enabling resources, and perceived and evaluated need for care. The intervention seeks to improve engagement with overdose and HIV prevention services by addressing barriers across each of these domains during an emergency department encounter.
Evaluation of implementation outcomes is guided by the Practical, Robust, Implementation and Sustainability Model (PRISM). PRISM provides a framework for understanding the interaction between the intervention, recipients, organizational context, external environment, and implementation infrastructure, and will inform refinement of the intervention and planning for future scale-up.
Years 2-3: Participant enrollment, intervention delivery, follow-up assessments, and implementation evaluation (Aims 2 and 3).
Year 3: Data analysis, dissemination of findings, and development of a future multicenter effectiveness-implementation trial.
56 studies on the registry are indexed under Harm Reduction; 32 are open to participants now.
This study's planned enrollment of 120 is below the median of 161 across 45 interventional studies indexed under Harm Reduction.
Browse Harm Reduction studies →Johns Hopkins University is the lead sponsor of 1,809 studies on the registry; 314 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive the PROTECT-ED intervention during the index emergency department encounter. The intervention consists of systematic identification; peer-delivered prevention services; same-day offer and initiation of MOUD and PrEP, when clinically appropriate; harm reduction services; and facilitated linkage to ongoing community care. Clinical decisions regarding medication initiation remain the responsibility of the treating emergency department clinician. The ED clinician would prescribe medication as part of ED care delivery, this would include reviewing eligibility and dosing with the ED pharmacist.
Behavioral: PROTECT-ED Care Coordination
Participants will receive the PROTECT-ED intervention during the index emergency department encounter. The intervention consists of systematic identification; peer-delivered prevention services; same-day offer and initiation of MOUD and PrEP, when clinically appropriate; harm reduction services; and facilitated linkage to ongoing community care. Clinical decisions regarding medication initiation remain the responsibility of the treating emergency department clinician. The ED clinician would prescribe medication as part of ED care delivery, this would include reviewing eligibility and dosing with the ED pharmacist.
MOUD uptake
Proportion of participants initiating MOUD
Time frame: 0-26 Weeks
MOUD and PrEP Uptake
Proportion of participants initiating MOUD and PrEP
Time frame: 0-26 Weeks
PrEP Uptake
Proportion of participants initiating PrEP
Time frame: 0-26 Weeks
MOUD persistence at 6 months
Proportion of participants on MOUD at 6 months among those who initiated
Time frame: 26 Weeks
PrEP persistence at 6 months
Proportion of participants on PrEP at 6 months among those who initiated
Time frame: 26 Weeks
Participants with Repeat emergency department utilization
Repeat emergency department utilization across Baltimore City
Time frame: 0-26 Weeks
Opioid overdose events
Proportion of participants with 1+ opioid overdose events
Time frame: 0-26 Weeks
Linkage and engagement in longitudinal care
Proportion of participants linked to care
Time frame: 0-26 Weeks
Start is estimated for Nov 2026; primary completion for Oct 2027, 11 months later.
Of 34 interventional studies with no phase under Harm Reduction, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 50. This study's planned 11 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.